GRN-300

N/A

Report date: 2024/01/30 20:00:37
NMEFirst In Class

Base Information

Drug NameGRN-300
Drug Alias NameGRN-300GRN300ARN-3261
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSalt-inducible kinase 3 inhibitorsSerine/threonine-protein kinase SIK2 inhibitors
TargetsSalt-inducible kinase 3Serine/threonine-protein kinase SIK2
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArrien Pharmaceuticals Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGreenfire Bio LLCGreen3Bio Inc
Active IndicationsN/A
Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A